clinical trial · NCT06736509
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
Agitation in Patients With Dementia of the Alzheimer's TypeAlzheimer DiseaseAgitation, PsychomotorAXS-05 (dextromethorphan-bupropion)
brief summary
The primary objective of this open-label extension trial is to evaluate the long-term safety of AXS-05 for the treatment of Alzheimer's disease agitation in subjects that participated in ADVANCE-2 and ACCORD-2.
started
Nov 21, 2024
primary completion
Feb 17, 2025
completion
Apr 25, 2025
last updated
Feb 19, 2026
detailed description
This is a multi-center, open-label extension trial to evaluate the long-term safety of AXS-05 in subjects with Alzheimer's disease (AD) agitation that wish to continue to receive AXS-05 given completion of ADVANCE-2 (AXS-05-AD-304) and ACCORD-2 (AXS-05-AD-303).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol